The in vitro HAART pharmacodynamics study with dolutegravir as the "anchor" / 药学学报
Acta Pharmaceutica Sinica
;
(12): 50-58, 2015.
Article
in Chinese
| WPRIM
| ID: wpr-251818
ABSTRACT
This study is to evaluate the HAART pharmacodynamics with dolutegravir as the "anchor" in vitro. A nucleoside reverse transcriptase inhibitors (NRTIs) resistant recombinant virus model (VSVG/HIV-1(RT-D67N,K70R,T215F)) and an integrase inhibitors (INIs) resistant recombinant virus model (VSVG/HIV-1(IN-G140S,QI48H)) were constructed and established. The anti-viral pharmacodynamics was evaluated with drug combinations including two NRTIs along with one INI or one NNRTI. The results showed that the combination with an INI gave a stronger synergism on wild type HIV-1 replication comparing to that with an NNRTI. Comparing the two INIs as the "anchor" for HAART, DTG exhibited an equivalent CI to that of RAL on wild type HIV-1 replication; but a greater synergy than RAL on INI-resistant HIV-1 replication. Besides of the pharmacodynamics results of DTG-based drug combination, the results may contribute to clinical antiviral therapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pharmacology
/
Physiology
/
Virus Replication
/
Cells, Cultured
/
HIV-1
/
HIV Integrase Inhibitors
/
Antiretroviral Therapy, Highly Active
/
Drug Resistance, Viral
/
Heterocyclic Compounds, 3-Ring
Limits:
Humans
Language:
Chinese
Journal:
Acta Pharmaceutica Sinica
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS